<DOC>
	<DOCNO>NCT00423800</DOCNO>
	<brief_summary>This Phase IIIB randomize , control , multi-centre , open-label study 24 versus 48 week therapy Pegetron® ( peginterferon alfa-2b + ribavirin ) standard dose naïve Hepatitis C Virus ( HCV ) genotype 1 high viral load ( HVL ) participant Hepatitis C Virus-Ribonucleic Acid ( HCV-RNA ) negative Week 4 . HVL define HCV-RNA &gt; 600,000 IU/mL prior initiation therapy . Participants genotype 1 baseline HVL prescribe Pegetron® ( peginterferon ribavirin ) usual manner accordance marketing authorization viral negative Week 4 randomize Week 8 receive total 24 48 week therapy . Participants required baseline Week-12 viral load analyze local laboratory use standard care test use site . Qualitative test Week 4 , 8 , 16-20 , 24 , 48 may conduct either local laboratory central laboratory identify sponsor use assay specify sponsor . No additional intervention outside clinic 's standard care condition Canadian product monograph Pegetron® apply participant .</brief_summary>
	<brief_title>Efficacy Safety 24 vs 48 Weeks Pegetron® ( Peginterferon Alfa-2b + Ribavirin ) Naïve Genotype 1 Hepatitis C ( Study P05016 ) ( TERMINATED )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Must demonstrate willingness participate study . Diagnosed chronic HCV . Between 18 65 year age either gender race . a. HCV positive , &gt; 600,000 IU/mL baseline AND b. Genotype 1 . Suitable treatment Pegetron® per Canadian product monograph . Investigator already decide treat PEGETRON REDIPEN® 1.5mcg/kg/week peginterferon alpha2b plus 8001200 mg /day ribavirin . HCVRNA negative treatment week 4 . Meet certain minimum laboratory value week 4 screening visit . Women childbearing potential male partner must agree use medically accept method contraception prior screening , receive protocolspecified medication , 6 month stop medication . Acceptable method contraception include condom ( male female ) without spermicidal agent , diaphragm cervical cap spermicide , medically prescribe IUD , oral injectable hormonal contraceptive , surgical sterilization ( e.g . hysterectomy tubal ligation ) . Had previous interferonbased therapy Chronic Hepatitis C. Active Hepatitis B virus ( HBV ) infection . Human Immunodeficiency Virus ( HIV ) antibody positive . Cirrhotic ( Stage 4 Metavir system ) . Uncontrolled history current severe depression psychosis . Uncontrolled epilepsy . Use illicit drug . History noncompliance medical regimen . Liver disease chronic hepatitis C. Participating clinical study . Used investigational drug within 30 day screen . Participants weigh &lt; 40 kg &gt; 125 kg . Pregnant woman woman plan become pregnant sexual partner woman want become pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>